Cargando…

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis

BACKGROUND: Anticoagulant treatment is used to treat and prevent venous thromboembolism (VTE). However, the relative effectiveness of newer anticoagulants vs. warfarin has not been appraised. OBJECTIVE: The aim was to evaluate the safety and efficacy of rivaroxaban for VTE in comparison to warfarin....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhuang, Song, Dan, Wang, Liang, Wang, Changfeng, Zhou, Jie, Sun, Jiali, Guo, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149967/ https://www.ncbi.nlm.nih.gov/pubmed/37139185 http://dx.doi.org/10.3389/fsurg.2023.1086871

Ejemplares similares

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis
por: Xing, Jiali, et al.
Publicado: (2018)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban
por: Piati, Polyana Klomfass, et al.
Publicado: (2019)

Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
por: Du, Wei, et al.
Publicado: (2015)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban()
por: Colleoni, Jose Luiz, et al.
Publicado: (2017)

Rivaroxaban for cancer-associated venous thromboembolism: A systematic review and meta-analysis protocol
por: Liang, Bo, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2023)

Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences
por: Cohen, Alexander T., et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Rivaroxaban and Acetylsalicylic Acid for Prevention of Venous Thromboembolism Following Total Knee Arthroplasty in Korean Patients
por: Chung, Kyu Sung, et al.
Publicado: (2018)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
por: Berger, Jeffrey S., et al.
Publicado: (2022)

Incidence and Risk Factors of Venous Thromboembolism in Patients After Transurethral Resection of the Prostate (TURP)
por: Zheng, Zhihuan, et al.
Publicado: (2022)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
por: Speed, Victoria, et al.
Publicado: (2021)

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
por: Witt, Daniel M., et al.
Publicado: (2016)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Rivaroxaban versus aspirin in prevention of venous thromboembolism following total joint arthroplasty or hip fracture surgery: a meta-analysis
por: Hu, Bangsheng, et al.
Publicado: (2021)

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
por: Khorana, Alok A., et al.
Publicado: (2017)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Cost-Effectiveness Rivaroxaban versus Enoxaparin for Prevention of Venous Thromboembolism after Knee Replacement Surgery in Iran
por: Abutorabi, Ali, et al.
Publicado: (2023)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Atenolol vs. propranolol for the treatment of infantile haemangiomas: A systematic review and meta-analysis
por: Liu, Zhuang, et al.
Publicado: (2020)

Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure
por: Martinez, Brandon K., et al.
Publicado: (2018)

Effectiveness of Polidocanol in the Treatment of Venous Malformations: A Meta-Analysis
por: Hu, Wei, et al.
Publicado: (2022)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9i4jd1kui75kco9phmqi04lghn